

# Marjorie G Zauderer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5319752/publications.pdf>

Version: 2024-02-01

49  
papers

3,501  
citations

201385

27  
h-index

205818

48  
g-index

51  
all docs

51  
docs citations

51  
times ranked

4449  
citing authors

| #  | ARTICLE   | IF    | CITATIONS |
|----|---|-------|-----------|
| 1  | Molecular Characterization of Peritoneal Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2022, 17, 455-460.  | 0.5   | 24        |
| 2  | Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. <i>Lung Cancer</i> , 2022, 165, 1-9.  | 0.9   | 15        |
| 3  | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.  | 13.5  | 223       |
| 4  | Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459.   | 1.1   | 10        |
| 5  | EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 758-767.  | 5.1   | 49        |
| 6  | Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice. <i>Oncologist</i> , 2022, 27, 610-614.  | 1.9   | 2         |
| 7  | The therapeutic implications of the genomic analysis of malignant pleural mesothelioma. <i>Nature Communications</i> , 2021, 12, 1819.  | 5.8   | 3         |
| 8  | A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-“PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.   | 7.7   | 222       |
| 9  | The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. <i>The Lancet Digital Health</i> , 2021, 3, e565-e576.   | 5.9   | 23        |
| 10 | Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy. <i>Journal of Immunotherapy</i> , 2021, Publish Ahead of Print, .   | 1.2   | 3         |
| 11 | V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. <i>Modern Pathology</i> , 2020, 33, 303-311.  | 2.9   | 65        |
| 12 | Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry. <i>American Journal of Industrial Medicine</i> , 2020, 63, 105-114.  | 1.0   | 12        |
| 13 | Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 402-429.   | 157.7 | 306       |
| 14 | Nivo-lution in Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5438-5440.   | 3.2   | 7         |
| 15 | Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. <i>Genome Medicine</i> , 2019, 11, 18.  | 3.6   | 36        |
| 16 | Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667. | 0.5   | 85        |
| 17 | Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.   | 7.7   | 422       |
| 18 | Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study. <i>International Journal of Cancer</i> , 2017, 140, 1976-1984.   | 2.3   | 35        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses $\text{NF-}\kappa\text{B}$ -Driven Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1693-1704.   | 1.9 | 31        |
| 20 | Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 61-69. | 0.4 | 19        |
| 21 | Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 993-1000.  | 0.5 | 53        |
| 22 | A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489.  | 3.2 | 48        |
| 23 | Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. <i>Current Cancer Research</i> , 2017, , 313-345.  | 0.2 | 1         |
| 24 | Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. <i>Oncotarget</i> , 2017, 8, 77872-77882.   | 0.8 | 31        |
| 25 | Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?. <i>Lancet Oncology</i> , The, 2016, 17, e43-e44.  | 5.1 | 28        |
| 26 | Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2761-2768.                         | 0.8 | 154       |
| 27 | Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive $\text{ALK}$ -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.  | 1.9 | 119       |
| 28 | Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2874-2884.  | 3.2 | 103       |
| 29 | Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 249-255.   | 0.5 | 53        |
| 30 | A new standard for malignant pleural mesothelioma. <i>Lancet</i> , The, 2016, 387, 1352-1354.  | 6.3 | 14        |
| 31 | Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016, 11, e0146063.   | 1.1 | 17        |
| 32 | Localized malignant pleural mesothelioma with renal metastasis. <i>Oxford Medical Case Reports</i> , 2015, 2015, 170-172.  | 0.2 | 11        |
| 33 | A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non-Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1272-1277.   | 0.5 | 33        |
| 34 | Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. <i>Lung Cancer</i> , 2014, 86, 237-240.  | 0.9 | 47        |
| 35 | Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 394-401.  | 0.4 | 55        |
| 36 | Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014, 84, 271-274.   | 0.9 | 101       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Toxicity of initial chemotherapy in older patients with lung cancers. <i>Journal of Geriatric Oncology</i> , 2013, 4, 64-70.  | 0.5 | 18        |
| 38 | Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1430-1433.  | 0.5 | 81        |
| 39 | New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment. <i>Clinical Cancer Research</i> , 2012, 18, 4485-4490.   | 3.2 | 77        |
| 40 | Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1278-1283.  | 0.4 | 142       |
| 41 | Novel and Targeted Therapies. , 2012, , 95-101.   |     | 0         |
| 42 | Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 487-90. | 0.6 | 9         |
| 43 | Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 42-47.  | 2.3 | 22        |
| 44 | The Evolution of Multimodality Therapy for Malignant Pleural Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2011, 12, 163-172.  | 1.3 | 37        |
| 45 | Leptomeningeal Metastases from Small Cell Lung Cancer Responsive to Temozolomide Therapy. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1716-1717.   | 0.5 | 5         |
| 46 | Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 205-210.   | 1.1 | 48        |
| 47 | Developing a cancer-specific geriatric assessment. <i>Cancer</i> , 2005, 104, 1998-2005.  | 2.0 | 541       |
| 48 | Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 151-156.   | 1.1 | 47        |
| 49 | Change in Cycle 1 to Cycle 2 Haematological Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy. <i>Drugs and Aging</i> , 2005, 22, 709-715.  | 1.3 | 13        |